Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets

BMC Systems Biology

Table 1 17 potential drug targets ranked by sum of degree of perturbation ≥ 8 in Supplementary Tables 2 and 3

Protein targets	Sum of degree of perturbation	Agents	Literature review
BCL2	35	G3139 (Genasense), ABT-737	[4, 29, 33–36, 38]
CASP3	22	Synthetic activators of caspases/Apoptin/IAP targets surviving	[33, 34, 36]
BAX	17	Gene therapy through Bax vectors	[34]
TP53	17	ONY-015/INGN201/MDM2 inhibitors	[4, 34, 38, 39]
BCL2L1	13	Antisense BCL-xL	[34]
CDKN1A	13		[43]
TNF	10		[4, 34]
EGFR	9	Trastuzumab (Herceptin)	[34]
MAPK1	9	CI-1040/PD0325901/ARRY-142886	[41, 42]
MAPK3	9	CI-1040/PD0325901/ARRY-142886	[41, 42]
MYC	9	Bortezomib (Proteosome Inhibitors)	[40]
BID	8		[34]
CASP9	8	Caspases activators/Apoptin/surviving	[33, 34, 36]
CCND1	8		[44]
CFLAR	8		[23]
CYCS	8		[37, 38]
TNFRSF6	8		[34]

ISSN: 1752-0509